Quanterix Corp QTRX

Technology SIC 3826 - Laboratory Analytical Instruments NAICS Manufacturing › Computer and Electronic Product Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing › Analytical Laboratory Instrument Manufacturing derived Nasdaq

We are a life sciences company transforming healthcare innovation by accelerating biomarker breakthroughs from discovery to diagnostics using our ultra-sensitive translational research and spatial biology instruments, consumables, and services. We continue to invest in pushing a paradigm shift in healthcare from an emphasis on later-stage treatment to a focus on earlier detection, monitoring, prognosis, and, ultimately, prevention. Our combined platforms have achieved significant commercial adoption with an installed base of over 2,500 instruments and scientific validation with citations in more than 6,200 scientific publications in areas of high unmet medical need and research interest such as neurology, oncology, immunology, and inflammation.

Last close 2.86 2026-10-23
Market cap $135.3M 2026-06-30 share count
52-week range 2.15 - 8.77

Valuation FY2025 figures against the last close

P/S1.0x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.51

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $138.9M$137.4M$122.4M$105.5M$110.6M$86.4M$56.7M$37.6M$22.9M$17.6M
Cost of revenue $73.9M$54.3M$48.1M$60.2M$45.8M$38.2M$29.9M$19.7M$12.9M$9.8M
Gross profit $65.0M$83.1M$74.2M$45.4M$64.8M$48.2M$26.8M$17.9M$10.0M$7.7M
R&D $35.9M$31.1M$26.1M$26.8M$28.4M$20.2M$16.2M$15.8M$16.3M$17.0M
SG&A $138.0M$101.6M$89.1M$91.9M$92.9M$59.6M$52.2M$33.7M$19.7M$12.5M
Total operating expenses $190.5M$135.7M$120.2M$149.6M$121.3M$79.8M$68.4M$49.5M$36.0M$29.5M
Operating income -$125.5M-$52.6M-$46.0M-$104.3M-$56.5M-$31.6M-$41.6M-$31.6M-$26.0M-$21.7M
Interest expense $8.6M$14.7M$15.8M$5.1M$403.0K$273.0K$627.0K$46.0K$951.0K$1.3M
Pre-tax income -$112.3M-$38.1M-$27.6M-$99.4M-$55.6M-$31.9M-$41.0M-$31.5M-$27.0M-$23.2M
Income tax $5.1M$434.0K$719.0K$164.0K$36.0K$376.0K$187.0K$25.0K$0—
Net income -$107.2M-$38.5M-$28.4M-$99.6M-$55.5M-$31.5M-$40.8M-$31.5M-$27.0M-$23.2M
EPS, basic -2.51-1.00-0.75-2.69-1.54-1.07-1.63———
EPS, diluted -2.51-1.00-0.75-2.69-1.54-1.07-1.63———
Shares, diluted (wtd. avg.) 42.6M38.4M37.6M37.0M36.0M29.6M25.1M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $29.8M$56.7M$177.0M$341.3M$399.3M$182.6M$110.2M$45.4M$79.7M$29.7M
Short-term investments $88.4M$232.4M$146.9M$0——————
Receivables $30.0M$32.1M$25.4M$19.7M$22.6M$17.2M$10.9M$6.8M$5.6M—
Inventory $54.8M$32.8M$26.1M$22.7M$24.4M$14.9M$10.5M$5.9M$3.6M—
Total current assets $212.3M$363.6M$382.1M$413.9M$435.5M$219.6M$132.7M$59.5M$89.3M—
Property, plant and equipment $23.7M$17.1M$17.9M$22.0M$19.6M$13.9M$12.0M$2.9M$1.9M—
Goodwill $26.4M$0$0$8.7M$9.3M$10.5M$9.4M$1.3M——
Other intangibles $131.8M$4.0M$6.0M$8.5M$9.7M$13.7M$14.3M$2.3M——
Total assets $418.8M$406.5M$428.6M$488.7M$506.7M$271.0M$170.0M$67.6M$91.8M—
Accounts payable $13.6M$7.0M$5.0M$5.9M$4.2M$6.8M$5.8M$5.1M$3.6M—
Short-term debt —————$7.7M$75.0K—$5.0M—
Total current liabilities $74.8M$42.0M$39.0M$36.7M$31.8M$39.8M$19.8M$18.1M$19.7M—
Long-term debt —————$7.7M$7.6M$7.6M$4.3M—
Total liabilities $123.0M$76.5M$78.6M$83.2M$78.2M$64.9M$41.3M$26.5M$25.9M—
Retained earnings -$577.2M-$470.1M-$431.6M-$348.4M-$321.5M-$247.8M-$216.2M-$175.9M-$144.4M—
Total equity $295.7M$330.0M$350.0M$357.9M$442.8M$205.8M$128.7M$41.1M$65.9M-$115.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$77.2M-$35.2M-$18.8M-$48.6M-$47.6M-$23.4M-$26.2M-$28.7M-$22.1M-$17.7M
Depreciation and amortisation $15.8M$6.5M$6.3M$5.4M$4.9M$4.3M$3.0M$1.4M$482.0K$444.0K
Stock-based compensation $20.7M$20.0M$16.8M$15.4M$16.0M$10.1M$6.4M$4.9M$2.2M$928.0K
Capital expenditure $2.6M$3.4M$3.8M$11.6M$13.7M$3.9M$10.8M$1.5M$1.1M$526.0K
Investing cash flow $50.2M-$82.3M-$148.5M-$11.1M-$6.4M-$626.0K-$25.4M-$5.5M-$1.1M-$826.0K
Financing cash flow -$708.0K$456.0K$2.7M$2.3M$270.8M$96.2M$116.2M-$78.0K$73.2M$45.9M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-048166.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M -100M 0 100M 200M Revenue, FY2016: 17.6M Gross profit, FY2016: 7.7M Net income, FY2016: -23.2M Revenue, FY2017: 22.9M Gross profit, FY2017: 10M Net income, FY2017: -27M Revenue, FY2018: 37.6M Gross profit, FY2018: 17.9M Net income, FY2018: -31.5M Revenue, FY2019: 56.7M Gross profit, FY2019: 26.8M Net income, FY2019: -40.8M Revenue, FY2020: 86.4M Gross profit, FY2020: 48.2M Net income, FY2020: -31.5M Revenue, FY2021: 110.6M Gross profit, FY2021: 64.8M Net income, FY2021: -55.5M Revenue, FY2022: 105.5M Gross profit, FY2022: 45.4M Net income, FY2022: -99.6M Revenue, FY2023: 122.4M Gross profit, FY2023: 74.2M Net income, FY2023: -28.4M Revenue, FY2024: 137.4M Gross profit, FY2024: 83.1M Net income, FY2024: -38.5M Revenue, FY2025: 138.9M Gross profit, FY2025: 65M Net income, FY2025: -107.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $17.6M $22.9M $37.6M $56.7M $86.4M $110.6M $105.5M $122.4M $137.4M $138.9M
Gross profit $7.7M $10.0M $17.9M $26.8M $48.2M $64.8M $45.4M $74.2M $83.1M $65.0M
Net income -$23.2M -$27.0M -$31.5M -$40.8M -$31.5M -$55.5M -$99.6M -$28.4M -$38.5M -$107.2M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3826

TickerCompanyMarket capP/ERevenue growth
A AGILENT TECHNOLOGIES, INC. $48.79B 37.9x 6.7%
WAT WATERS CORP /DE/ $44.57B 42.2x 7.0%
ILMN ILLUMINA, INC. $40.68B 49.4x -0.7%
MTD METTLER TOLEDO INTERNATIONAL INC/ $33.47B 39.7x 4.0%
RVTY REVVITY, INC. $17.72B 76.7x 3.7%
AVTR Avantor, Inc. $11.80B — -3.4%
BIO BIO-RAD LABORATORIES, INC. $9.89B 13.3x 0.7%
TXG 10x Genomics, Inc. $9.30B — 5.2%